NCT02643784Unknown4 期
Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 100
- 主要终点
- Percent changes in infarction volumes measured by MRI on the 14th day compared with the baseline of the stroke
研究概览
简要总结
This is an exploratory, randomized, open-label, 2-arm, parallel-group study exploring the efficacy of rosuvastatin (20mg/day) in patients with acute ischemic stroke.
详细描述
This is a 90-day, explanatory; randomized; open-label, 2-arm; parallel group with blinded outcome evaluation study exploring the efficacy and study of early rosuvastatin 20 mg/d treatment in acute ischemic patients with stroke onset in 24 hours.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •45 to 75 years old patients;
- •Stroke involving the vascular territory of the middle cerebral artery (MCA) as judged by clinical and MRI evidences;
- •Time from symptom onset to take the study assigned medication is within 24 hours;
- •Statin naïve or discontinued at least 3 month before stroke onset;
- •First ever stroke or mild sequelae (with modified Rankin Score 0-1) before the index event;
- •Moderate neurological deficit with baseline NIHSS scoring from 4-20;
- •MRI scans （T1W1、T2W2、T2Flair、DWI、SWI）accomplished from 12 to 48 hours after the onset;
- •Consent form signed.
排除标准
- •Any of the following is regarded as a criterion for exclusion from the study:
- •Stroke involving the vascular territory of the vertebrobasilar artery as judged by clinical and MRI evidences;
- •Hemorrhagic transformation or intracranial hemorrhage on baseline MRI. MRI performed between 12-48 hours after the onset, if MRI provides evidences which met with the exclusion criteria, the patients will be excluded from the study;
- •Any circumstances under which MRI scans can't be performed;
- •Evidences suggesting cardiogenic stroke such as atrial fibrillation, acute coronary syndrome, patent foramen ovale , etc;
- •Comatose with NIHSS 1a>1;
- •Medical or psychiatric conditions such as severe hepatic or renal dysfunction, heart failure, malignancy, major depression, dementia, alcohol or drug abuse;
- •Suitable for rt-Plasminogen Activator thrombolysis treatment;
- •Receiving medication with possible neuroprotective functions after stroke onset;
- •Currently take steroids therapy;
- •Diagnosed with malignancy within 5 years;
- •Patients with myopathy or serum creatine kinase > 3 times the upper limit of normal not caused by myocardial injury;
- •Severe renal function damage (eGFR<30);
- •Concurrent use ciclosporin;
- •A history of hypersensitivity of statins and other severe complication;
- •Child-bearing women ;
- •Patients who are or may be pregnant;
- •Other conditions under which patients not pertinent to attend the study as judged by the investigators.
研究组 & 干预措施
Rosuvastatin
Experimental
Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
干预措施: Rosuvastatin (Drug)
Rosuvastatin
Experimental
Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
干预措施: Control (Other)
结局指标
主要结局
Percent changes in infarction volumes measured by MRI on the 14th day compared with the baseline of the stroke
时间窗: 0-14d
次要结局
- Absolute changes in infarction volumes measured by MRI on the 14th day compared with the baseline of the stroke(0-14d)
- The functional outcome measured by modified Rankin Scale (14,90 days), compared between statin group and standard group(14-90d)
- The neurological outcomes measured by NIHSS (14,90 days), compared between statin group and standard group(14-90d)
- The rate of the new-onset infarct assessed by MRI from baseline to 14th day, compared between statin group and standard group(0-14d)
- Proportion of patients whose infarction volume reduced on the 14th day compared with the baseline of the stroke(0-14d)
研究者
相似试验
已完成
3 期
DISCOVERY Asia - Crestor in Type IIa and IIb HypercholesteremiaHypercholesterolemiaNCT00241488AstraZeneca1,362
已完成
1 期
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy SubjectsPharmacokineticsNCT04092725Scynexis, Inc.36
尚未招募
不适用
Prospective Randomized Trial of the Effects of Rosuvastatin on the Progression of Stenosis in Adult Patients with Congenital Aortic Stenosis.Aortic valve stenosis, congenital heart defectsNL-OMON24714Erasmus Medical Center, Rotterdam, Department of Cardiology180
已完成
2 期
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance HemodialysisEnd Stage Renal DiseaseAnemiaNCT01147666FibroGen161
Unknown
4 期
Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)Kidney FailureNCT02447822Asan Medical Center154